Pharmaceutical Genomics Division, Cancer Drug Development Laboratory~Applying genomic technologies, primarily RNA interference, to identify particular mechanisms, biomarkers and contexts by which market and clinical drugs can be used to treat cancers. All this is done with the overall goal of translating these findings to improve and accelerate the effectiveness of how we select and treat patients with various types of cancer.These approaches can be utilized towards:1. 'Personalized medicine' approaches, where the right patient is matched with the right drug therapeutic.2. Guiding the development of new clinical therapeutics by pharmaceutical companies3. Repositioning the use of existing marketed therapeutics.Responsible for:*Design, assay development and optimization and execution of high-throughput RNA interference (HT-RNAi) screens with whole human genome siRNA libraries*Development of other functional and secondary assays that validate and support hits identified from HT-RNAi.*Development of in-vitro drug combination studies that are used to bridge & assess the potential of newly identified gene targets in the clinical setting.

Lead Discovery Department~Application of a proprietory small molecule compound library to identify and develop agonists and antogonists of nuclear & cellular receptor, and kinase targets in a variety disease states such as cancer, metabolism and inflammation.Responsible for:*Assay development and optimization to ultra-high throughput levels (1536 well format) via using a wide variety of liquid dispensing, plate handling and automation equipment.*High Throughput Screening*Support of medicinal chemists through SAR (Structural Activity Relationship) assays of potential lead compounds identified through screens. Provided quality in-vitro biological assay data using the same assays incorporated in the screens within short turnaround times upon receipt of compounds from the chemists.*Develop and optimize functional and secondary assays that support lead candidate optimization towards clinical application.

Lead Discovery Department, HTS Division~Identification of potential small molecule inhibitors of various kinase & phosphatase targets that have therapeutic potential.Responsible for:*High Throughput Screening of small molecule compounds against a large panel of protein kinases and phosphatases through the use of radiometric (kinase) and colorimetric (phosphatase) assays.*Support of medicinal chemists through SAR (Structural Activity Relationship) assays of potential lead compounds identified through screens. Provided quality in-vitro biological assay data using the same assays incorporated in the screens within short turnaround times upon receipt of compounds from the chemists.*Protein expression and purification of protein kinases and phosphatases used in assays. Quality Control & Assurance was also performed and emphasized for all prepared samples.